Liu, Q., Hou, L., Zhao, Y., Yang, H., Mo, Z., & Yu, F. (2023). Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer. Clinics, 78, 100291. https://doi.org/10.1016/